Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
475.91
-2.67 (-0.56%)
At close: Oct 28, 2025, 4:00 PM EDT
476.02
+0.11 (0.02%)
After-hours: Oct 28, 2025, 6:45 PM EDT

Alnylam Pharmaceuticals Stock Forecast

Stock Price Forecast

The 26 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $466.46, which forecasts a -1.99% decrease in the stock price over the next year. The lowest target is $298 and the highest is $583.

Price Target: $466.46 (-1.99%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$298$466.46$475$583
Change-37.38%-1.99%-0.19%+22.50%

Analyst Ratings

The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingMay '25Jun '25Jul '25Aug '25Sep '25Oct '25
Strong Buy111113131413
Buy989101111
Hold333443
Sell111000
Strong Sell000000
Total242326272927

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Truist Securities
Truist Securities
Strong Buy
Maintains
$459$535
Strong BuyMaintains$459$535+12.42%Oct 17, 2025
JP Morgan
JP Morgan
Buy
Maintains
$475$473
BuyMaintains$475$473-0.61%Oct 13, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$570
Strong BuyReiterates$570+19.77%Oct 10, 2025
Morgan Stanley
Morgan Stanley
Hold
Maintains
$405$475
HoldMaintains$405$475-0.19%Oct 6, 2025
Stifel
Stifel
Strong Buy
Maintains
$441$495
Strong BuyMaintains$441$495+4.01%Oct 6, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
3.60B
from 2.25B
Increased by 60.04%
Revenue Next Year
5.06B
from 3.60B
Increased by 40.69%
EPS This Year
1.39
from -2.18
EPS Next Year
5.76
from 1.39
Increased by 313.17%
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
492.85M844.29M1.04B1.83B2.25B3.60B5.06B
Revenue Growth
124.28%71.31%22.88%76.24%22.97%60.04%40.69%
EPS
-7.46-7.20-9.30-3.52-2.181.395.76
EPS Growth
------313.17%
Forward PE
-----341.5782.67
No. Analysts
-----3231
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High4.0B8.0B
Avg3.6B5.1B
Low3.2B4.1B

Revenue Growth

Revenue Growth20252026202720282029
High
79.3%
122.1%
Avg
60.0%
40.7%
Low
44.5%
13.2%

EPS Forecast

EPS20252026202720282029
High3.8613.91
Avg1.395.76
Low-1.110.12

EPS Growth

EPS Growth20252026202720282029
High-
898.5%
Avg-
313.2%
Low-
-91.6%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.